Showing 5501-5510 of 5771 results for "".
- Eye Health America Acquires Montgomery & Riddle Eyecare and The Surgery and Laser Center at Professional Parkhttps://modernod.com/news/eye-health-america-acquires-montgomery-riddle-eyecare-in-south-carolina/2479957/Eye Health America (EHA) announced its acquisition of Montgomery & Riddle Eyecare and The Surgery & Laser Center at Professional Park, an eye care provider in South Carolina. Terms of the deal were not disclosed. The acquisition of Montgomery & Riddle Eyecare strengthens
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient
- Aerie Pharmaceuticals and DSM Biomedical Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmologyhttps://modernod.com/news/aerie-pharmaceuticals-and-dsm-biomedical-expand-collaboration-agreement-focused-on-novel-drug-delivery-technology-in-ophthalmology/2479966/Aerie Pharmaceuticals and DSM Biomedical reported that they have expanded their collaborative research, development, and license agreement. In July 2017, Aerie announced that it had entered into a research collaboration and license option agreement with DSM for purposes of evaluating the s
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience
- RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapyhttps://modernod.com/news/radiancetx-raises-1-million-first-tranche-to-develop-novel-glaucoma-therapy/2479970/RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three cli
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- AAO Launches New Scientific Journal Dedicated to Glaucoma Researchhttps://modernod.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/The American Academy of Ophthalmology announced the launch of Ophthalmology Glaucoma, a scientific journal focused exclusively on glaucoma. As development of next-generation glaucoma devices and drugs surges, Ophthalmology Glaucoma offers researchers an expanded opportunity to pu
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Topical Presbyopia Treatment Advances in Clinical Developmenthttps://modernod.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/Presbyopia Therapies announced that the primary efficacy and safety endpoints have been met in a phase 2b study of its PRX ophthalmic solution. PRX demonstrated a 3 line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improve
- Clearside Biomedical Phase 3 PEACHTREE Trial Results Presented at ASRShttps://modernod.com/news/clearside-biomedical-phase-3-peachtree-trial-results-presented-at-asrs/2479980/Steven Yeh, MD, presented data from the phase 3 PEACHTREE trial at the American Society of Retina Specialists annual meeting as a late-breaking oral presentation. This was the first public presentation of data from PEACHTREE, a pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macul